Iontophoresis-aided drug delivery into the eyeball via eyelid skin

See, Gerard Lee; Sagesaka, Ayano; Torizuka, Hazuki; Todo, Hiroaki; Sugibayashi, Kenji

doi:10.1016/j.jddst.2018.08.001

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Routes Of Administration For Treating Ocular Diseasesmentioning

confidence: 99%

“…Iontophoresis uses a voltage gradient to deliver drugs to the back of the eye and has been shown to be effective for delivering nanoparticles and drugs loaded in contact lenses [31,32]. Iontophoretic delivery has also been developed for pilocarpine and besifloxacin-loaded liposomes [33,34] The suprachoroidal space (SCS) is being explored as a potential approach to target pharmacotherapies to the posterior segment via a minimally invasive injection procedure Clinical trials have explored the efficacy and safety of suprachoroidal injection of pharmacologic therapies in conditions affecting the posterior segment, with promising results for non-infectious uveitis. Suprachoroidal administration also shows potential for other applications, such as an injection of antiglaucoma agents into the anterior SCS and delivery of gene-or cell-based therapies for retinal disorders [35] Figure 3 illustrates the different routes of administration for ophthalmic medications including topical, subconjunctival, suprachoroidal, intracameral, intravitreal, retrobulbar sub-tenon, posterior juxta scleral, subretinal, and systemic administration.…”

Section: Routes Of Administration For Treating Ocular Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

Joly-Chevrier

Akbar

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Posterior segment eye diseases present a challenge in treatment due to the complex structures in the eye that serve as robust static and dynamic barriers, limiting the penetration, residence time, and bioavailability of topical and intraocular medications. This hinders effective treatment and requires frequent dosing, such as the regular use of eye drops or visits to the ophthalmologist for intravitreal injections, to manage the disease. Moreover, the drugs must be biodegradable to minimize toxicity and adverse reactions, as well as small enough to not affect the visual axis. The development of biodegradable nano-based drug delivery systems (DDSs) can be the solution to these challenges. First, they can stay in ocular tissues for longer periods of time, reducing the frequency of drug administration. Second, they can pass through ocular barriers, offering higher bioavailability to targeted tissues that are otherwise inaccessible. Third, they can be made up of polymers that are biodegradable and nanosized. Hence, therapeutic innovations in biodegradable nanosized DDS have been widely explored for ophthalmic drug delivery applications. In this review, we will present a concise overview of DDSs utilized in the treatment of ocular diseases. We will then examine the current therapeutic challenges faced in the management of posterior segment diseases and explore how various types of biodegradable nanocarriers can enhance our therapeutic arsenal. A literature review of the pre-clinical and clinical studies published between 2017 and 2023 was conducted. Through the advances in biodegradable materials, combined with a better understanding of ocular pharmacology, the nano-based DDSs have rapidly evolved, showing great promise to overcome challenges currently encountered by clinicians.

show abstract

Section: Routes Of Administration For Treating Ocular Diseasesmentioning

confidence: 99%

Section: Routes Of Administration For Treating Ocular Diseasesmentioning

confidence: 99%

Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

Joly-Chevrier

Akbar

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…An electric current (typically <0.5 mA/cm 2 ) is applied on the skin to drive the charged molecule by the electrophoresis force, along with the resulting electroosmotic flow from ions in the solvent 3 . Recent study on the iontophoresis drug delivery have clearly demonstrated the effectiveness and the advantages of this technique 4‐12 …”

Section: Introductionmentioning

confidence: 99%

Electrically controlled transdermal delivery of naproxen and indomethacin from porous cis‐1,4‐polyisoprene matrix

et al. 2021

View full text Add to dashboard Cite

This study is focused on the inquiry of using a porous polymeric structure to absorb and release transdermally two drugs through a skin from deproteinized natural rubber latex (DPNR). The porous DPNR films were fabricated from the internal formation of surfactant micelles and their subsequent leaching out to generate porous structures. The pore size of DPNR films increased with increasing surfactant amount. The model drugs were naproxen and indomethacin; their releases and release‐permeations were investigated under the effects of surfactant amount, electrical potential, and drug size. Without electric field, the drug release mechanism was mainly driven by concentration gradient. The higher amount of drug released was obtained from the matrix with a larger pore size. Under electric field, the higher amounts of drug release were obtained in the shorter drug release durations, via the electrorepulsive force between the negatively charged drugs and the cathode electrode. The molecular drug size was a factor for the drug absorption, release rate and amount. For the drug release‐permeation experiment through the pig skin, there were two release‐permeation periods as governed by the combination of concentration gradient and swelling in the first period, and the matrix erosion in the second period. The fabricated porous DPNR films have been shown here to be potential to be used as a transdermal patch with electrically controllable drug release rate, amount and duration along with the facile drug‐matrix loading and absorption.

show abstract

“…Several works have validated the capacity of the eyelids to support the delivery of drugs into the ocular tissues. [2][3][4][5] Our previous work showed that topical application of drugs onto the eyelids yielded high absorption in the conjunctiva and the eyeball, which was mainly be attributed to the thin skin barrier, the stratum corneum, and lower amounts of neutral lipids in the eyelid skin. 5) Tranilast, anthranilic acid, is a lipophilic drug which have wide applications against ocular conditions such as allergic conjunctivitis, 6) prevention of post-operative adhesion after strabismus surgery, 7) treatment of corneal allergic inflammation, 8) and prevention of fibrous opacification of the posterior lens capsule after cataract extraction 9) among others.…”

Section: Introductionmentioning

confidence: 99%

Prolonged Distribution of Tranilast in the Eyes after Topical Application onto Eyelid Skin

See

Arce

Itakura

et al. 2020

CHEMICAL & PHARMACEUTICAL BULLETIN

Self Cite

View full text Add to dashboard Cite

Tranilast, a lipophilic drug with various ophthalmic applications, was used as a model drug to establish the possibility of delivering lipophilic drugs through the eyelid skin. Pharmacokinetics and tissue distribution studies were conducted employing three application methods (topical application onto eyelid skin, eye drops, and intravenous injection in rats) to broaden the significance of delivering drugs through the eyelids.A two-compartment open model analysis was used for intravenous route while a non-compartmental evaluation was used for topical applications to estimate the pharmacokinetic parameters. Eyelid skin application, eye drops, and intravenous administration had mean residence times (MRTs) of 8.07, 1.79, and 3.25 h in the eyeball and 10.8, 1.29, and 2.97 h in the conjunctiva, correspondingly. In the eyeball, topical application of tranilast onto the eyelids corresponded to a 4.5-and 2.5-fold higher MRT compared with eye drops and intravenous administration, respectively. An 8.4-or 3.6-fold higher MRT was observed in the conjunctiva after topical application compared with eye drops or intravenous administration, respectively. This indicated a gradual penetration of tranilast into the eyeball and conjunctiva, subsequently a slow elimination from these target tissues.

show abstract

Iontophoresis-aided drug delivery into the eyeball via eyelid skin

Cited by 6 publications

References 23 publications

Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

Electrically controlled transdermal delivery of naproxen and indomethacin from porous cis‐1,4‐polyisoprene matrix

Prolonged Distribution of Tranilast in the Eyes after Topical Application onto Eyelid Skin

Contact Info

Product

Resources

About